Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trialKohei Shitara, Mustafa Özgüroğlu, Yung‐Jue Bang et al.|The Lancet|2018Cited by 1.3k
Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trialGunnar Folprecht, Claus‐Henning Köhne, Thomas Gruenberger et al.|The Lancet Oncology|2009Cited by 960
Nivolumab plus Ipilimumab in Microsatellite-Instability–High Metastatic Colorectal CancerThierry André, Sara Lonardi, Michael Schenker et al.|New England Journal of Medicine|2024Cited by 208
Perioperative Atezolizumab Plus Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel for Resectable Esophagogastric Cancer: Interim Results From the Randomized, Multicenter, Phase II/III DANTE/IKF-s633 TrialSylvie Lorenzen, Thorsten Oliver Götze, Peter Thuss‐Patience et al.|Journal of Clinical Oncology|2023Cited by 192